Evidence mapPaperPMID 41355840Full record

ArticleBehavioural neurology2025

4-Methylumbelliferone (4-MU) Improves Learning and Memory After Cerebral Ischemia/Reperfusion Injury in Rats.

Shaghayegh Tamouk, Hamzeh Mirshekari Jahangiri, Elham Kashafi Jahromi, Michael R Hamblin, Nahid Aboutaleb, Fatemeh Ramezani

Abstract read
In one paragraph

Article in Behavioural neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shaghayegh TamoukPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir.
Hamzeh Mirshekari JahangiriPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir.ORCID https://orcid.org/0000-0002-7186-467X
Elham Kashafi JahromiDepartment of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir.
Michael R HamblinLaser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa, uj.ac.za.ORCID https://orcid.org/0000-0001-6431-4605
Nahid AboutalebPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir.ORCID https://orcid.org/0000-0002-7514-5939
Fatemeh RamezaniPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran, iums.ac.ir.ORCID https://orcid.org/0000-0002-8545-3521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Stroke is the sixth leading cause of death and lifelong disability for millions of people in the United States. Cerebral ischemia leads to oxidative stress, excitotoxicity, inflammation, and apoptosis; additionally, impairment in memory and learning occurs in the majority of subjects with ischemic stroke. The lack of definitive treatment has sparked extensive research into novel therapeutic strategies, including the use of 4-methylumbelliferone (4-MU), a coumarin derivative with potential neuroprotective properties. The present study examines the impact of 4-MU on reducing cerebral ischemia-reperfusion (I/R) injury and learning and memory impairments in male Wistar rats. Methods: Animals were exposed to middle cerebral artery occlusion (MCAO) and treated with a single dose of 4-MU (25 mg/kg) dissolved in 0.9% DMSO. An automated shuttle box and Morris water maze (MWM) tests were employed to evaluate learning and memory impairments. Western blot assay, TTC staining, and Nissl staining were used to measure protein expression, infarct volume, and cell death, respectively. Results: Treatment with 4-MU reduced infarct volume and improved learning and memory impairments by downregulating HAS1 and HAS2. 4-MU modulated the release of proinflammatory cytokines including TNF- Conclusion: The neuroprotective effects of 4-MU against cerebral I/R injury can be attributed to the downregulation of HAS1 and HAS2.

Indexed as

Brain IschemiaLearningMemoryNeuroprotective AgentsReperfusion InjuryUmbelliferonesAnimalsDisease Models, AnimalInfarction, Middle Cerebral ArteryMaleMaze LearningMemory DisordersOxidative StressRatsRats, WistarNeuroprotective AgentsUmbelliferones4-methylumbelliferonehyaluronan synthasesischemic strokelearning and memory impairmentsMCAOneuronal death

Identifiers

PMID41355840
PMCPMC12680788

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.